Search

Your search keyword '"Woie, Kathrine"' showing total 144 results
Start Over Author "Woie, Kathrine"
144 results on '"Woie, Kathrine"'

9. #870 Radiomic profiles improve prognostication and reveal targets for therapy in cervical cancer

Author

Halle, Mari Kyllesø, primary, Hodneland, Erlend, additional, Wagner-Larsen, Kari S, additional, Lura, Njål G, additional, Fasmer, Kristine E, additional, Berg, Hege F, additional, Stokowy, Thomasz, additional, Srivastava, Aashish, additional, Forsse, David, additional, Hoivik, Erling A, additional, Woie, Kathrine, additional, Bertelsen, Bjørn I, additional, Krakstad, Camilla, additional, and Haldorsen, Ingfrid S, additional

Published
2023
Full Text
View/download PDF

13. Mismatch repair markers in preoperative and operative endometrial cancer samples; expression concordance and prognostic value

Author

Berg, Hege F., primary, Engerud, Hilde, additional, Myrvold, Madeleine, additional, Lien, Hilde E., additional, Hjelmeland, Marta Espevold, additional, Halle, Mari K., additional, Woie, Kathrine, additional, Hoivik, Erling A., additional, Haldorsen, Ingfrid S., additional, Vintermyr, Olav, additional, Trovik, Jone, additional, and Krakstad, Camilla, additional

Published
2022
Full Text
View/download PDF

17. 2022-RA-905-ESGO Mismatch repair deficiency is not applicable as biomarker in cervical cancer, yet MSH-2 has strong prognostic value

Author

van den Berg, Madeleine Charlotte, primary, Berg, Hege Fredriksen, additional, Stokowy, Thomas, additional, Hoivik, Erling, additional, Woie, Kathrine, additional, Engerud, Hilde, additional, Ojesina, Akinyemi I, additional, Salvesen Haldorsen, Ingfrid Helene, additional, Bertelsen, Bjørn Inge, additional, Trovik, Jone, additional, Halle, Mari Kyllesø, additional, and Krakstad, Camilla, additional

Published
2022
Full Text
View/download PDF

21. Abstract 513: Radiomic profiles revealing targets for therapy in cervical cancer

Author

Halle, Mari Kyllesø, primary, Hodneland, Erlend, additional, Hoivik, Erling, additional, Wagner-Larsen, Kari, additional, Lura, Njål G., additional, Dybvik, Julie, additional, Forsse, David, additional, Bertelsen, Bjørn I., additional, Krakstad, Camilla, additional, Haldorsen, Ingfrid S., additional, Bozickovic, Olivera, additional, and Woie, Kathrine, additional

Published
2022
Full Text
View/download PDF

22. Longitudinal effects of adjuvant chemotherapy and lymph node staging on patient-reported outcomes in endometrial cancer survivors: a prospective cohort study

Author

Forsse, David, primary, Barbero, Mark L., additional, Werner, Henrica M.J., additional, Woie, Kathrine, additional, Nordskar, Nina, additional, Berge Nilsen, Elisabeth, additional, Ellstrøm Engh, Marie, additional, Vistad, Ingvild, additional, Rege, Astri, additional, Sævik-Lode, Margaret, additional, Andreasen, Stine, additional, Haldorsen, Ingfrid S., additional, Trovik, Jone, additional, and Krakstad, Camilla, additional

Published
2022
Full Text
View/download PDF

24. A Gene Signature Identifying CIN3 Regression and Cervical Cancer Survival

Author

Halle, Mari K., primary, Munk, Ane Cecilie, additional, Engesæter, Birgit, additional, Akbari, Saleha, additional, Frafjord, Astri, additional, Hoivik, Erling A., additional, Forsse, David, additional, Fasmer, Kristine E., additional, Woie, Kathrine, additional, Haldorsen, Ingfrid S., additional, Bertelsen, Bjørn I., additional, Janssen, Emiel A. M., additional, Gudslaugsson, Einar, additional, Krakstad, Camilla, additional, and Øvestad, Irene T., additional

Published
2021
Full Text
View/download PDF

25. Landscape of genomic alterations in cervical carcinomas

Author

Ojesina, Akinyemi I., Lichtenstein, Lee, Freeman, Samuel S., Pedamallu, Chandra Sekhar, Imaz-Rosshandler, Ivan, Pugh, Trevor J., Cherniack, Andrew D., Ambrogio, Lauren, Cibulskis, Kristian, Bertelsen, Bjørn, Romero-Cordoba, Sandra, Treviño, Victor, Vazquez-Santillan, Karla, Guadarrama, Alberto Salido, Wright, Alexi A., Rosenberg, Mara W., Duke, Fujiko, Kaplan, Bethany, Wang, Rui, Nickerson, Elizabeth, Walline, Heather M., Lawrence, Michael S., Stewart, Chip, Carter, Scott L., McKenna, Aaron, Rodriguez-Sanchez, Iram P., Espinosa-Castilla, Magali, Woie, Kathrine, Bjorge, Line, Wik, Elisabeth, Halle, Mari K., Hoivik, Erling A., Krakstad, Camilla, Gabiño, Nayeli Belem, Gómez-Macías, Gabriela Sofia, Valdez-Chapa, Lezmes D., Garza-Rodríguez, María Lourdes, Maytorena, German, Vazquez, Jorge, Rodea, Carlos, Cravioto, Adrian, Cortes, Maria L., Greulich, Heidi, Crum, Christopher P., Neuberg, Donna S., Hidalgo-Miranda, Alfredo, Escareno, Claudia Rangel, Akslen, Lars A., Carey, Thomas E., Vintermyr, Olav K., Gabriel, Stacey B., Barrera-Saldaña, Hugo A., Melendez-Zajgla, Jorge, Getz, Gad, Salvesen, Helga B., and Meyerson, Matthew

Published
2014
Full Text
View/download PDF

26. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

Author

Matulonis, Ursula A., primary, Walder, Lydia, additional, Nøttrup, Trine J., additional, Bessette, Paul, additional, Mahner, Sven, additional, Gil-Martin, Marta, additional, Kalbacher, Elsa, additional, Ledermann, Jonathan A., additional, Wenham, Robert M., additional, Woie, Kathrine, additional, Lau, Susie, additional, Marmé, Frederik, additional, Casado Herraez, Antonio, additional, Hardy-Bessard, Anne-Claire, additional, Banerjee, Susana, additional, Lindahl, Gabriel, additional, Benigno, Benedict, additional, Buscema, Joseph, additional, Travers, Karin, additional, Guy, Holly, additional, and Mirza, Mansoor R., additional

Published
2019
Full Text
View/download PDF

27. Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial

Author

del Campo, Josep M., primary, Matulonis, Ursula A., additional, Malander, Susanne, additional, Provencher, Diane, additional, Mahner, Sven, additional, Follana, Philippe, additional, Waters, Justin, additional, Berek, Jonathan S., additional, Woie, Kathrine, additional, Oza, Amit M., additional, Canzler, Ulrich, additional, Gil-Martin, Marta, additional, Lesoin, Anne, additional, Monk, Bradley J., additional, Lund, Bente, additional, Gilbert, Lucy, additional, Wenham, Robert M., additional, Benigno, Benedict, additional, Arora, Sujata, additional, Hazard, Sebastien J., additional, and Mirza, Mansoor R., additional

Published
2019
Full Text
View/download PDF

29. Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial

Author

Matulonis, Ursula A., Walder, Lydia, Nøttrup, Trine J, Bessette, Paul, Mahner, Sven, Gil-Martin, Marta, Kalbacher, Elsa, Ledermann, Jonathan A, Wenham, Robert M, Woie, Kathrine, Lau, Susie, Marmé, Frederik, Casado Herraez, Antonio, Hardy-Bessard, Anne-Claire, Banerjee, Susana, Lindahl, Gabriel, Benigno, Benedict, Buscema, Joseph, Travers, Karin, Guy, Holly, Mirza, Mansoor R., Matulonis, Ursula A., Walder, Lydia, Nøttrup, Trine J, Bessette, Paul, Mahner, Sven, Gil-Martin, Marta, Kalbacher, Elsa, Ledermann, Jonathan A, Wenham, Robert M, Woie, Kathrine, Lau, Susie, Marmé, Frederik, Casado Herraez, Antonio, Hardy-Bessard, Anne-Claire, Banerjee, Susana, Lindahl, Gabriel, Benigno, Benedict, Buscema, Joseph, Travers, Karin, Guy, Holly, and Mirza, Mansoor R.

Abstract

This study estimated time without symptoms or toxicity (TWiST) with niraparib compared with routine surveillance (RS) in the maintenance treatment of patients with recurrent ovarian cancer.

Published
2019
Full Text
View/download PDF

31. Cervical cancer staging, pretreatment planning, and surgical treatment in the Nordic countriesSurvey from the Surgical Subcommittee of the Nordic Society of Gynecological Oncology

Author

Fuglsang, Katrine, Haldorsen, Ingfrid S., Åvall-Lundqvist, Elisabeth, Lindahl, Gabriel, Roed, Henrik, Woie, Kathrine, Pakarinen, Paivi, Thoroddsen, Asgeir, Anttila, Maarit, Blaakaer, Jan, Fuglsang, Katrine, Haldorsen, Ingfrid S., Åvall-Lundqvist, Elisabeth, Lindahl, Gabriel, Roed, Henrik, Woie, Kathrine, Pakarinen, Paivi, Thoroddsen, Asgeir, Anttila, Maarit, and Blaakaer, Jan

Abstract

IntroductionWomen with cervical cancer in the Nordic countries are increasingly undergoing pretreatment imaging by ultrasound, magnetic resonance imaging (MRI), positron emission tomography-computed tomography (PET-CT) or computed tomography, or sentinel lymph node procedure. The present survey reports the influence of pretreatment imaging findings on the recorded clinical International Federation of Gynecology and Obstetrics (FIGO) stage in Nordic countries and its impact on treatment planning and preferred surgical approach in cervical cancer. Material and methodsThe Nordic Society of Gynecological Oncology Surgical Subcommittee developed a questionnaire-based survey that was conducted from 1 January to 31 March 2017. All the 22 Nordic Gynecological Oncology Centers (Denmark 5, Finland 5, Iceland 1, Norway 4, and Sweden 7) were invited to participate. ResultsThe questionnaires were returned by 19 of 22 (86.3%) centers. The median number (range) of women with cervical cancer treated at each center annually was 32 (15-120). In 58% (11/19) of the centers, imaging findings were reported to influence the clinical staging. MRI in combination with PET-CT was the preferred imaging method and the results influenced treatment planning. Robotic-assisted radical hysterectomy was the preferred surgical method in 72% (13/18) of the centers. Sentinel lymph node procedure was not routinely implemented in the majority of the Nordic centers. ConclusionMore than half of the Nordic Gynecological Oncology Centers already report a clinical FIGO stage influenced by pretreatment imaging findings. The trend in preferred treatment is robotic-assisted radical hysterectomy and the sentinel lymph node procedure is gradually being introduced.

Published
2018
Full Text
View/download PDF

32. Cervical cancer staging, pretreatment planning, and surgical treatment in the Nordic countries-Survey from the Surgical Subcommittee of the Nordic Society of Gynecological Oncology

Author

Fuglsang, Katrine, primary, Haldorsen, Ingfrid S, additional, Avall-Lundqvist, Elisabeth, additional, Lindahl, Gabriel, additional, Roed, Henrik, additional, Woie, Kathrine, additional, Pakarinen, Päivi, additional, Thoroddsen, Asgeir, additional, Anttila, Maarit, additional, and Blaakaer, Jan, additional

Published
2018
Full Text
View/download PDF

33. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)

Author

Lindemann, Kristina, Gibbs, Emma, Åvall-Lundqvist, Elisabeth, dePont Christensen, Rene, Woie, Kathrine, Kalling, Marten, Auranen, Annika, Grenman, Seija, Hoegberg, Thomas, Rosenberg, Per, Skeie-Jensen, Tone, Hjerpe, Elisabet, Dorum, Anne, Gebski, Val, Kristensen, Gunnar, Lindemann, Kristina, Gibbs, Emma, Åvall-Lundqvist, Elisabeth, dePont Christensen, Rene, Woie, Kathrine, Kalling, Marten, Auranen, Annika, Grenman, Seija, Hoegberg, Thomas, Rosenberg, Per, Skeie-Jensen, Tone, Hjerpe, Elisabet, Dorum, Anne, Gebski, Val, and Kristensen, Gunnar

Abstract

Background: Chemotherapy in platinum-resistant ovarian cancer (PROC) aims for palliation and prolonging of progression-free survival (PFS). This study compares Health-related Quality of Life (HRQoL) and efficacy between single-agent chemotherapy and tamoxifen in PROC. Methods: Patients with PROC were randomised (2 : 1) to chemotherapy (weekly paclitaxel 80 mg m(-2) or four weekly pegylated liposomal doxorubicin 40 mg m(-2)) or tamoxifen 40mg daily. The primary end point was HRQoL. Secondary end points were PFS by RECIST and overall survival (OS). Results: Between March 2002 and December 2007, 156 and 82 patients were randomised to chemotherapy and tamoxifen, respectively. In the chemotherapy arm, a significantly larger proportion of patients experienced a worsening in their social functioning. There was no difference in the proportion of patients experiencing improvement of gastrointestinal symptoms. Median PFS on tamoxifen was 8.3 weeks (95% CI, 8.0-10.4) compared with 12.7 weeks (95% CI, 9.0-16.3) on chemotherapy (HR, 1.54; 95% CI, 1.16-2.05; log-rank P = 0.003). There was no difference in OS between the treatment arms. Conclusions: Patients on chemotherapy had longer PFS but experienced more toxicity and poorer HRQoL compared with tamoxifen. Control over gastrointestinal symptoms was not better on chemotherapy. These data are important for patient counselling and highlight the need to incorporate HRQoL end points in studies of PROC.

Published
2017
Full Text
View/download PDF

34. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Author

Mirza, Mansoor R, Monk, Bradley J, Herrstedt, Jørn, Oza, Amit M, Mahner, Sven, Redondo, Andrés, Fabbro, Michel, Ledermann, Jonathan A, Lorusso, Domenica, Vergote, Ignace, Ben-Baruch, Noa E, Marth, Christian, Madry, Radoslaw, Christensen, René D, Berek, Jonathan S, Dørum, Anne, Tinker, Anna V, du Bois, Andreas, González-Martín, Antonio, Follana, Philippe, Benigno, Benedict, Rosenberg, Per, Gilbert, Lucy, Rimel, Bobbie J, Buscema, Joseph, Balser, John P, Agarwal, Shefali, Matulonis, Ursula A, Lund, Bente, Malander, Susanne, Woie, Kathrine, Hellman, Kristina, Nøttrup, Trine Juhler, Havsteen, Hanne, Sehouli, Jalid, Harter, Philipp, Canzler, Ulrich, Lück, Hans-Joachim, Wölber, Linn, Marmé, Frederik, Meier, Werner, Heubner, Martin, Hilpert, Felix, Emons, Günter, Burges, Alexander, Bover Barcelo, Isabel Maria, Gil Martín, Marta, Palacio Vázquez, Isabel, Casado Herráez, Antonio, Maria del Campo, José, Lesoin, Anne, Berton-Rigaud, Dominique, N'Guyen, Thierry, Hardy-Bessard, Anne-Claire, Banerjee, Susana, Lord, Rosemary, Waters, Justin, Montes, Ana, Chan, Stephen, Williams, Sarah J, Barlow, Claire, Mullard, Anna, Colombo, Nicoletta, Scambia, Giovanni, Tognon, Germana, Scollo, Paolo, Kridelka, Frédéric, Leroy, Chantal, Debruyne, Philip, Huizing, Manon, Rosengarten, Ora, Levy, Talia, Frommer, Ronnie Shapira, Fishman, Ami, Edelman, David, Safra, Tamar, Amit, Amnon, Pikiel, Joanna, Suzin, Jacek, Mackowiak-Matejczyk, Beata, Reinthaller, Alexander, Petru, Edgar, Csoszi, Tibor, Bessette, Paul, Provencher, Diane, Lau, Susie, Ellard, Susan, Ghatage, Prafull, Moore, Kathleen, Wenham, Robert, Pineda, Mario, Azodi, Masoud, Mantia-Smaldone, Gina, Cloven, Noelle, Bailey, Cheryl, Lee, Christine, Secord, Angeles, Patel, Manish, Method, Michael, Callahan, Michael, Veena, John, Chan, John, Zarwan, Corrine, DiSilvestro, Paul, Teneriello, Michael, Gupta, Divya, Geller, Melissa, Burris, Howard, Slomovitz, Brian, Hendrickson, Andrea Wahner, McCormick, Colleen, Hanjani, Parviz, Blank, Stephanie, Haluska, Paul, Matei, Daniela, Vasilev, Stephen, Neidhart, Jeffrey, Boente, Matthew, Tchabo, Nana, Miller, David, and Targeted Gynaecologic Oncology (TARGON)

Subjects
0301 basic medicine, Oncology, Medizin, Genes, BRCA1, Platinum Compounds, POLY(ADP-RIBOSE) POLYMERASE, Kaplan-Meier Estimate, 030226 pharmacology & pharmacy, chemistry.chemical_compound, 0302 clinical medicine, Piperidines, Maintenance therapy, Bone Marrow, Medicine, Merck Sharp & Dohme, Homologous Recombination, Indazoles/adverse effects, Ovarian Neoplasms, Aged, 80 and over, Platinum compounds, OLAPARIB, Ovarian Neoplasms/drug therapy, Obstetrics and Gynecology, Bone Marrow/drug effects, General Medicine, Middle Aged, SOLID TUMORS, BRCA MUTATION CARRIERS, 030220 oncology & carcinogenesis, TRIAL, Female, Platinum sensitive, Adult, Piperidines/adverse effects, medicine.medical_specialty, Indazoles, Adolescent, Antineoplastic Agents, Disease-Free Survival, Olaparib, Maintenance Chemotherapy, Young Adult, 03 medical and health sciences, Platinum Compounds/therapeutic use, Double-Blind Method, Internal medicine, Humans, Rucaparib, Germ-Line Mutation, Aged, Neoplasm Staging, Cancer och onkologi, business.industry, Antineoplastic Agents/adverse effects, NEGATIVE BREAST-CANCER, 030104 developmental biology, chemistry, Recurrent Ovarian Cancer, Cancer and Oncology, Johnson Johnson, business
Abstract

BACKGROUND Niraparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) 1/2 inhibitor that has shown clinical activity in patients with ovarian cancer. We sought to evaluate the efficacy of niraparib versus placebo as maintenance treatment for patients with platinum-sensitive, recurrent ovarian cancer. METHODS In this randomized, double-blind, phase 3 trial, patients were categorized according to the presence or absence of a germline BRCA mutation (gBRCA cohort and non-gBRCA cohort) and the type of non-gBRCA mutation and were randomly assigned in a 2: 1 ratio to receive niraparib (300 mg) or placebo once daily. The primary end point was progression-free survival. RESULTS Of 553 enrolled patients, 203 were in the gBRCA cohort (with 138 assigned to niraparib and 65 to placebo), and 350 patients were in the non-gBRCA cohort (with 234 assigned to niraparib and 116 to placebo). Patients in the niraparib group had a significantly longer median duration of progression-free survival than did those in the placebo group, including 21.0 vs. 5.5 months in the gBRCA cohort (hazard ratio, 0.27; 95% confidence interval [CI], 0.17 to 0.41), as compared with 12.9 months vs. 3.8 months in the non-gBRCA cohort for patients who had tumors with homologous recombination deficiency (HRD) (hazard ratio, 0.38; 95% CI, 0.24 to 0.59) and 9.3 months vs. 3.9 months in the overall non-gBRCA cohort (hazard ratio, 0.45; 95% CI, 0.34 to 0.61; P amp;lt; 0.001 for all three comparisons). The most common grade 3 or 4 adverse events that were reported in the niraparib group were thrombocytopenia (in 33.8%), anemia (in 25.3%), and neutropenia (in 19.6%), which were managed with dose modifications. CONCLUSIONS Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded by Tesaro; ClinicalTrials.gov number, NCT01847274.) Funding Agencies|Tesaro; Amgen; Genentech; Roche; AstraZeneca; Myriad Genetics; Merck; Gradalis; Cerulean; Vermillion; ImmunoGen; Pfizer; Bayer; Nu-Cana BioMed; INSYS Therapeutics; GlaxoSmithKline; Verastem; Mateon Therapeutics; Pharmaceutical Product Development; Clovis Oncology; Janssen/Johnson Johnson; Eli Lilly; Merck Sharp Dohme

Published
2016

35. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer

Author

Ytre-Hauge, Sigmund, primary, Esmaeili, Morteza, additional, Sjøbakk, Torill E, additional, Grüner, Renate, additional, Woie, Kathrine, additional, Werner, Henrica M, additional, Krakstad, Camilla, additional, Bjørge, Line, additional, Salvesen, Øyvind O, additional, Stefansson, Ingunn M, additional, Trovik, Jone, additional, Bathen, Tone F, additional, and Haldorsen, Ingfrid S, additional

Published
2017
Full Text
View/download PDF

36. Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study

Author

Njølstad, Tormund S., primary, Werner, Henrica M., additional, Marcickiewicz, Janusz, additional, Tingulstad, Solveig, additional, Staff, Anne C., additional, Oddenes, Klaus, additional, Bjørge, Line, additional, Engh, Marie E., additional, Woie, Kathrine, additional, Tjugum, Jostein, additional, Lode, Margaret S., additional, Amant, Frederic, additional, Salvesen, Helga B., additional, and Trovik, Jone, additional

Published
2017
Full Text
View/download PDF

37. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers

Author

Berg, Anna, primary, Gulati, Ankush, additional, Ytre-Hauge, Sigmund, additional, Fasmer, Kristine E., additional, Mauland, Karen K., additional, Hoivik, Erling A., additional, Husby, Jenny A., additional, Tangen, Ingvild L., additional, Trovik, Jone, additional, Halle, Mari K., additional, Stefansson, Ingunn, additional, Akslen, Lars A., additional, Woie, Kathrine, additional, Bjørge, Line, additional, Salvesen, Helga B., additional, Salvesen, Øyvind O., additional, Werner, Henrica M.J., additional, Haldorsen, Ingfrid S., additional, and Krakstad, Camilla, additional

Published
2017
Full Text
View/download PDF

38. Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)

Author

Lindemann, Kristina, primary, Gibbs, Emma, additional, Åvall-Lundqvist, Elisabeth, additional, dePont Christensen, Rene, additional, Woie, Kathrine, additional, Kalling, Marten, additional, Auranen, Annika, additional, Grenman, Seija, additional, Hoegberg, Thomas, additional, Rosenberg, Per, additional, Skeie-Jensen, Tone, additional, Hjerpe, Elisabet, additional, Dørum, Anne, additional, Gebski, Val, additional, and Kristensen, Gunnar, additional

Published
2017
Full Text
View/download PDF

39. Lowering of interstitial fluid pressure after neurogenic inflammation is inhibited by mystixin-7 peptide

Author

GJERDE, ELI-ANNE B., WOIE, KATHRINE, WEI, EDWARD T., and REED, ROLF K.

Subjects
Soft tissue injuries -- Physiological aspects, Anti-inflammatory drugs -- Usage, Inflammation -- Physiological aspects, Peptides -- Usage, Biological sciences
Abstract

Lowering of interstitial fluid pressure after neurogenic inflammation is inhibited by mystixin-7 peptide. Am J Physiol Heart Circ Physiol 279: H1377-H1382, 2000.--Soft tissue injury is accompanied by lowering of interstitial fluid pressure ([P.sub.if]), plasma protein extravasation, and edema. Inflammation was produced by electrical stimulation (ES) of the vagus and the effects of the synthetic peptide mystixin-7 (p-anisoyl-Arg-Lys-Leu-Leu-D-Thi-Ile-D-Leu-[NH.sub.2]) on [P.sub.if] were examined. Micropuncture measurement of [P.sub.if] in submucosa, without opening the trachea, was conducted on rats anesthetized with pentobarbital sodium (50 mg/kg) and euthanized with intravenous KCI. [P.sub.if] in control (intravenous saline)was - 1.2 [+ or -] 0.7 mmHg before ES and decreased to - 4.7 [+ or -] 1.0 mmHg (P [is less than] 0.01, n = 8) after ES. Mystixin-7 (10 and 20 [micro]g/kg iv) blocked the fall in [P.sub.if] after ES (-1.1 [+ or -] 0.3 and -0.8 [+ or -] 0.2 mmHg, P [is less than] 0.01, n = 8 and n = 4). The 1 [micro]g/kg dose was without effect. When trachea from animals pretreated with mystixin-7 (20 [micro]g/kg iv) were soaked in phosphate-buffered saline (0.15 M, pH 7.4), the rate of fluid accumulation was significantly reduced. This study suggests that mystixin peptides, which have structural similarity to a fragment from laminin-[Alpha]1 chain, may be useful tools for studying cell adhesion and factors that maintain the structural integrity of connective tissue after injury. anti-inflammatory; rat; trachea; micropuncture

Published
2000

40. Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer

Author

Berg, Anna, primary, Fasmer, Kristine E., additional, Mauland, Karen K., additional, Ytre-Hauge, Sigmund, additional, Hoivik, Erling A., additional, Husby, Jenny A., additional, Tangen, Ingvild L., additional, Trovik, Jone, additional, Halle, Mari K., additional, Woie, Kathrine, additional, Bjørge, Line, additional, Bjørnerud, Atle, additional, Salvesen, Helga B., additional, Werner, Henrica M. J., additional, Krakstad, Camilla, additional, and Haldorsen, Ingfrid S., additional

Published
2016
Full Text
View/download PDF

41. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis

Author

Gibson, William J, primary, Hoivik, Erling A, additional, Halle, Mari K, additional, Taylor-Weiner, Amaro, additional, Cherniack, Andrew D, additional, Berg, Anna, additional, Holst, Frederik, additional, Zack, Travis I, additional, Werner, Henrica M J, additional, Staby, Kjersti M, additional, Rosenberg, Mara, additional, Stefansson, Ingunn M, additional, Kusonmano, Kanthida, additional, Chevalier, Aaron, additional, Mauland, Karen K, additional, Trovik, Jone, additional, Krakstad, Camilla, additional, Giannakis, Marios, additional, Hodis, Eran, additional, Woie, Kathrine, additional, Bjorge, Line, additional, Vintermyr, Olav K, additional, Wala, Jeremiah A, additional, Lawrence, Michael S, additional, Getz, Gad, additional, Carter, Scott L, additional, Beroukhim, Rameen, additional, and Salvesen, Helga B, additional

Published
2016
Full Text
View/download PDF

42. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer.

Author

Ytre-Hauge, Sigmund, Esmaeili, Morteza, Sjøbakk, Torill E., Grüner, Renate, Woie, Kathrine, Werner, Henrica M., Krakstad, Camilla, Bjørge, Line, Salvesen, Øyvind O., Stefansson, Ingunn M., Trovik, Jone, Bathen, Tone F., and Haldorsen, Ingfrid S.

Subjects
TUMOR grading, ENDOMETRIAL cancer, NUCLEAR magnetic resonance spectroscopy, CHOLINE, MYOMETRIUM, ENDOMETRIUM, LONGITUDINAL method, RESEARCH evaluation, ENDOMETRIAL tumors, PREDICTIVE tests, RECEIVER operating characteristic curves
Abstract

Background In vivo magnetic resonance spectroscopy (MRS) enables non-invasive measurements of tumor metabolites. Choline-containing metabolites play a key role in tumor metabolism. Purpose To explore whether preoperative MRS-derived tumor choline levels are associated with clinical and histological features in endometrial carcinomas. Material and Methods Preoperative pelvic magnetic resonance imaging (MRI) (1.5T), including structural and diffusion-weighted imaging and localized multivoxel proton MR (1H-MR) spectroscopy, was performed in 77 prospectively included patients with histologically confirmed endometrial carcinomas. Relative levels of total choline-containing metabolites (tCho) in tumor and myometrium were measured using the ratios: tCho/Creatine; tCho/Water; and tCho/Noise. MRS parameters were analyzed in relation to histological subtype and grade, surgicopathological staging parameters, MRI-measured tumor volume, and tumor apparent diffusion coefficient (ADC) value and clinical outcome. Results Tumor tissue had significantly higher ratios for tCho/Creatine, tCho/Water, and tCho/Noise than normal myometrial tissue ( P < 0.001 for all). High tumor tCho/Water ratio was significantly associated with high tumor grade in endometrioid tumors ( P = 0.02). Tumor tCho/Creatine ratio was positively correlated to MRI-measured tumor volume (rs = 0.25; P = 0.03). Conclusion High choline levels in tumor are associated with high-risk features. In vivo MRS may potentially aid in the preoperative risk stratification in endometrial cancer. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

43. A study of the interaction between a kinetic hydrate inhibitor and selected corrosion inhibitors

Author

Woie, Kathrine

Subjects
Technology: 500::Environmental engineering: 610 [VDP], teknisk miljøvern, offshore teknologi, Technology: 500::Marine technology: 580::Offshore technology: 581 [VDP]
Abstract

Master's thesis in Environmental technology In field operations where natural gas hydrates can occur and CO2 corrosion is a problem, chemicals called inhibitors can be employed. Kinetic hydrate inhibitors (KHIs) and corrosion inhibitors (CIs) are added in small concentrations to ensure flow assurance and for controlling CO2 corrosion. When production chemicals are mixed fatal interactions can arise. Previous studies have been carried out and interactions have been revealed between different commercial KHIs and CIs. Finding a compatible CI/KHI package is of great interest for oil field companies in order to control two hazardous issues during petroleum production. The purpose of this master’s thesis was to study interactions between a commercial KHI and three different CIs. Surface tension measurements were performed prior to the corrosion and hydrate testing. Finding critical micelle concentration (CMC) for each solution containing both inhibitors was needed for selecting the proper CI concentration. Two kinds of tests were performed for evaluating the chemical performance in the presence of one another. Corrosion testing was done in kettle tests by using the linear polarization technique. A hydrate rocking cell system was employed in the hydrate testing. CI efficiency and hydrate induction time was the parameters which were compared among the tests to reveal potential interactions. Corrosion test results revealed a trend of antagonism between the KHI and two of the CIs. The third CI was slightly improved in the presence of the KHI. Hydrate test results revealed an antagonistic effect of CI to KHI performance. The hydrate induction time was reduced by more than 50 % in nearly all the test. One of the inhibitor combinations showed moderately compatibility in both tests. Further research in this area could include a more detailed analysis of each couple to investigate what happens on a molecular level and at a surface. By understanding these mechanisms the search for a compatible CI/KHI package with certain qualities will be more efficient.

Published
2011

44. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study

Author

Høberg-Vetti, Hildegunn, primary, Bjorvatn, Cathrine, additional, Fiane, Bent E, additional, Aas, Turid, additional, Woie, Kathrine, additional, Espelid, Helge, additional, Rusken, Tone, additional, Eikesdal, Hans Petter, additional, Listøl, Wenche, additional, Haavind, Marianne T, additional, Knappskog, Per M, additional, Haukanes, Bjørn Ivar, additional, Steen, Vidar M, additional, and Hoogerbrugge, Nicoline, additional

Published
2015
Full Text
View/download PDF

47. Abstract 4692: Relationships between somatic genomic alterations, tumor stage and progression-free survival in cervical cancer

Author

Ojesina, Akinyemi I., primary, Murray, Bradley, additional, Bjorge, Line, additional, Woie, Kathrine, additional, Krakstad, Camilla, additional, Lichtenstein, Lee, additional, Pedamallu, Chandra Sekhar, additional, Taylor-Weiner, Amaro, additional, Freeman, Samuel S., additional, Cherniack, Andrew D., additional, Lawrence, Michael S., additional, Cibulskis, Kristian, additional, Carter, Scott L., additional, Walline, Heather, additional, Carey, Thomas E., additional, Vintermyr, Olav K., additional, Bertelsen, Bjorn, additional, Crum, Christopher P., additional, Getz, Gad, additional, Meyerson, Matthew, additional, and Salvesen, Helga B., additional

Published
2014
Full Text
View/download PDF

48. Landscape of genomic alterations in cervical carcinomas

Author

Ojesina, Akinyemi I., primary, Lichtenstein, Lee, additional, Freeman, Samuel S., additional, Pedamallu, Chandra Sekhar, additional, Imaz-Rosshandler, Ivan, additional, Pugh, Trevor J., additional, Cherniack, Andrew D., additional, Ambrogio, Lauren, additional, Cibulskis, Kristian, additional, Bertelsen, Bjørn, additional, Romero-Cordoba, Sandra, additional, Treviño, Victor, additional, Vazquez-Santillan, Karla, additional, Guadarrama, Alberto Salido, additional, Wright, Alexi A., additional, Rosenberg, Mara W., additional, Duke, Fujiko, additional, Kaplan, Bethany, additional, Wang, Rui, additional, Nickerson, Elizabeth, additional, Walline, Heather M., additional, Lawrence, Michael S., additional, Stewart, Chip, additional, Carter, Scott L., additional, McKenna, Aaron, additional, Rodriguez-Sanchez, Iram P., additional, Espinosa-Castilla, Magali, additional, Woie, Kathrine, additional, Bjorge, Line, additional, Wik, Elisabeth, additional, Halle, Mari K., additional, Hoivik, Erling A., additional, Krakstad, Camilla, additional, Gabiño, Nayeli Belem, additional, Gómez-Macías, Gabriela Sofia, additional, Valdez-Chapa, Lezmes D., additional, Garza-Rodríguez, María Lourdes, additional, Maytorena, German, additional, Vazquez, Jorge, additional, Rodea, Carlos, additional, Cravioto, Adrian, additional, Cortes, Maria L., additional, Greulich, Heidi, additional, Crum, Christopher P., additional, Neuberg, Donna S., additional, Hidalgo-Miranda, Alfredo, additional, Escareno, Claudia Rangel, additional, Akslen, Lars A., additional, Carey, Thomas E., additional, Vintermyr, Olav K., additional, Gabriel, Stacey B., additional, Barrera-Saldaña, Hugo A., additional, Melendez-Zajgla, Jorge, additional, Getz, Gad, additional, Salvesen, Helga B., additional, and Meyerson, Matthew, additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results